Faruqi & Faruqi Alerts Investors of Deadline for This Securities Class Action Against Aquestive Therapeutics

Investor Alert: Faruqi & Faruqi's Class Action Reminder

Faruqi & Faruqi, LLP, a prominent national securities law firm based in New York, is bringing attention to investors of Aquestive Therapeutics, Inc. regarding a crucial upcoming deadline. Investors have until May 4, 2026 to seek the position of lead plaintiff in a federal securities class action lawsuit that has been filed against the company.

The firm is actively investigating possible claims against Aquestive Therapeutics, which operates under the NASDAQ ticker symbol AQST. The allegations involve significant violations of federal securities laws, which include making misleading statements and failing to disclose critical details regarding the company’s New Drug Application (NDA) for Anaphylm.

In particular, the lawsuit highlights that the company downplayed significant human factors related to the use of its sublingual film, which is crucial for patient safety and efficacy. Investors who purchased or acquired stock in Aquestive between June 16, 2025, and January 8, 2026, are urged to take action, as the company’s stock value has seen a dramatic drop due to these allegations.

On January 9, 2026, the CEO of Aquestive Therapeutics revealed that the United States Food and Drug Administration (FDA) had identified deficiencies in the NDA that preclude further discussions about labeling and post-marketing commitments at that time. This disclosure resulted in a staggering decline of $2.30, or 37.04%, in the stock price, closing at approximately $3.91 per share.

This lawsuit represents a significant opportunity for affected investors to seek restitution for their financial losses. The appointed lead plaintiff will be someone who possesses a substantial financial stake in the actions taken by the class and will oversee the litigation for all class members. Interested parties have the option to either advocate for themselves or remain passive class members, with the understanding that their potential recovery is independent of their decision to take on the lead plaintiff role.

Faruqi & Faruqi also welcomes insights from individuals who may have information related to the company's practices. This includes former employees, whistleblowers, and shareholders. Confidentiality is assured for all communications.

For those looking for more information about the class action or who wish to participate, they can reach out directly to Josh Wilson, senior partner at Faruqi & Faruqi, at 877-247-4292 or 212-983-9330 (Ext. 1310). Moreover, further details can be found on the firm’s website at www.faruqilaw.com/AQST.

Stay informed on the latest updates regarding this case via social media platforms such as LinkedIn, X (formerly Twitter), or Facebook. This advertisement falls under attorney marketing, and prior results do not guarantee similar outcomes in future matters.

Faruqi & Faruqi primarily aims to protect the interests of investors and ensure they are well-informed of their legal rights and opportunities for restitution.